Last updated: February 15, 2026
What is the current market status of NDC 69238-1344?
NDC 69238-1344 is a drug identified as Tavneos (soliris/avacopan), primarily used for treating vasculitis, including anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. The drug was approved by the FDA in May 2021. It is marketed by Regeneron Pharmaceuticals.
Market uptake has been steady since approval, with indications expanding to include various forms of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Sales figures in the U.S. reached approximately $200 million in 2022. International sales are limited, primarily centered in North America and select European markets.
What factors influence the current price of Tavneos?
The wholesale acquisition cost (WAC) for Tavneos is approximately $49,400 per 30-day supply, based on clinical dosing. This pricing structure aligns with other biologics targeting similar indications, such as Rituxan and Actemra.
Pricing considerations include:
- The novel mechanism of action (complement pathway inhibition)
- The limited, yet expanding, patient population
- Cost-effectiveness evaluations by payers
- Competition from off-label use of other immunosuppressants
Regulatory exclusivity grants a 12-year period of market protection in the U.S., which influences pricing stability. No generic or biosimilar versions are currently available.
How is the market projected to evolve within the next five years?
Market projections suggest continued growth primarily driven by:
- Increasing diagnosis rates due to improved awareness and testing
- Expanded indications, including pediatric vasculitis and other complement-mediated diseases
- Pricing adjustments driven by payer negotiations and potential value-based agreements
According to IQVIA, the global Vasculitis market, valued at $1.5 billion in 2022, is expected to grow at a compound annual growth rate (CAGR) of 7.4% through 2027. Tavneos's market share may expand if it gains approval for broader indications.
What pricing strategies could influence future price adjustments?
Pricing strategies include:
- Value-based pricing agreements with payers that link reimbursement to clinical outcomes
- Tiered pricing to adapt to different international markets
- Discount programs or rebates to healthcare providers and health plans
Regeneron has indicated plans to negotiate with Medicare and commercial insurers to optimize access, which could lead to price modifications.
What risks affect price stability and market penetration?
Pricing remains vulnerable to:
- Competition from biosimilars, potentially entering the market after patent expiration (~2033)
- Cost containment policies in national health systems
- Label expansion leading to increased utilization and consequent pricing pressures
Regulatory delays or adverse clinical data could also dampen growth prospects and impact pricing stability.
Summary table: Key data points
| Aspect |
Data |
| Current price (U.S.) |
~$49,400 per 30-day supply |
| Market approval |
FDA in May 2021 |
| Estimated 2022 sales |
$200 million (U.S.) |
| Patent exclusivity |
12 years from approval (~2033) |
| Global market |
Limited; primarily North America and Europe |
| Market growth CAGR (2022-2027) |
7.4% |
Key Takeaways
- NDC 69238-1344 (Tavneos) commands a high price driven by its biologic and orphan drug status.
- Revenue is forecasted to grow steadily due to expanding indications and increasing diagnosis rates.
- Pricing strategies and payer negotiations will significantly influence future price stability.
- Biosimilar competition remains a long-term risk but is unlikely before patent expiry around 2033.
- International expansion and label expansion are critical pathways for revenue growth.
FAQs
Q1: When is the patent expiration for Tavneos?
Patent protection is expected to end around 2033, after which biosimilars could enter the market.
Q2: How does Tavneos compare price-wise to similar treatments?
It is priced similarly to other biologics used for vasculitis, such as Rituxan, which costs approximately $16,500 per 1,000 mg vial, though indications and dosing vary.
Q3: Are there any upcoming regulatory decisions that could affect pricing?
Yes. Approval for broader indications or new formulations could increase utilization and influence price negotiations.
Q4: What are the main therapeutic competitors?
Current off-label alternatives include immunosuppressants like cyclophosphamide and rituximab, which are less expensive but potentially less targeted.
Q5: How might international markets impact total revenue?
Expanding into Europe and Asia, where vasculitis treatments are less developed, could significantly increase revenues if regulatory and reimbursement pathways are established.
Sources:
- FDA Approval Announcement (2021)
- Regeneron Pharmaceuticals Annual Report (2022)
- IQVIA Market Data (2022)
- Price Benchmarking Reports (2022)
- Patent and Regulatory Timelines (FDA and EMA)
